Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Regeneron Pharmaceuticals is conducting a Phase 3 study titled ‘A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC).’ The study aims to evaluate the effectiveness of cemiplimab, an immune system-boosting drug, compared to standard surgery in treating early-stage CSCC. This research is significant as it explores a potentially less invasive treatment option for skin cancer patients.
The intervention being tested is cemiplimab, a drug designed to enhance the immune system’s ability to target and destroy cancer cells by binding to the PD-1 protein on immune cells. The study will compare this drug’s efficacy to the traditional surgical approach.
The study employs a randomized, parallel intervention model without masking, focusing primarily on treatment. Participants are randomly assigned to receive either cemiplimab or standard surgical care, allowing for a direct comparison of outcomes.
The study began on January 2, 2025, with its primary completion and estimated overall completion dates yet to be announced. The most recent update was submitted on July 8, 2025. These dates are crucial for tracking the study’s progress and anticipating when results might become available.
This clinical update could influence Regeneron’s stock performance and investor sentiment, as successful outcomes may position cemiplimab as a preferred treatment for early-stage CSCC, potentially impacting the competitive landscape in the oncology sector.
The study is ongoing, with further details accessible on the ClinicalTrials portal.